

PATENT

IN UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.:

7,151,100

Docket No: 103.022US1

Issue Date:

December 19, 2006

Patentee: Dennis A. Carson et al.

Customer No.: 21186

Confirmation No.: 4171

Title

INDOLE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER

REQUEST FOR CERTIFICATE OF CORRECTION

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

ATTN: CERTIFICATE OF CORRECTION BRANCH

It is requested that a Certificate of Correction be issued correcting printing errors appearing in the above-identified United States patent. Two copies of the text of the Certificate in the suggested form are enclosed.

Pursuant to 1.20(a), enclosed please find a check in the amount of \$100.00.

Issuance of the Certificate of Correction would neither expand nor contract the scope of the claims as properly allowed, and re-examination is not required.

The Examiner is authorized to charge any additional fees or credit overpayment to Deposit Certificate Account No.19-0743.

Respectfully Submitted

JUN 2 0 2007

DENNIS A. CARSON ET AL.

of Correction

06/18/2007 EEKUBAY1 00000007 7151100

01 FC:1811

100.00 OP

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 373-6900

. Held Shows Monique M/ Perdok Shonka

Reg. No: 42,989

MMP:si

CERTIFICATE UNDER 37 CFR § 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on this 14 day of June 2007

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO	: 7,151,100	Page (1) of 3
	. , , , , , , , , , , , , , , , , , , ,	. ago (1 / 0 i o

DATED : December 19, 2006

INVENTOR(S) : Carson et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the face page, in field (63), under "Related U.S. Application Data", in column 1, line 2, after "1999" insert - -, now Pat. No. 6,545,034 - -.

On the face page, in field (56), under "Foreign Patent Documents", in column 1, line 13, delete "WO-02/021225" and insert - - WO-02/02125 - -, therefor.

On page 2, in field (56), under "U.S. Patent Documents", in column 1, line 32, below "5,824,699" insert - - 5,939,455 8/1999 Rephaeli 514/547 - -.

On page 2, in field (56), under "U.S. Patent Documents", in column 1, line 43, below "2002/0042375" insert - - 2003/0004142 1/2003 Prior et al. 514/165 - -.

On page 2, in field (56), under "Other Publications", in column 2, lines 38-41, delete ""Treatment of Prostate Cancer: Watchful Waiting, Radical Prostatectomy, and Cryoablation", Seminars in Surgical Oncology, 18(1), pp. 37-44, Jan./Feb. 2000)" and insert - - "Enhancement of Chemotherapeutic Drug Toxicity to Human Tumour Cells In Vitro by a Subset of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)", European Journal of Cancer, 34 (8), pp. 1250-1259, (Jul. 1998). - -, therefor.

On page 2, in field (56), under "Other Publications", in column 2, line 61, below "1997)." insert - - Leman, Eddy S., et al., "Characterization of the Nuclear Matrix Proteins in a Transgenic Mouse Model for Prostate Cancer", Journal of Cellular Biochemistry, 86, (2002), 203-212.".

On page 3, in field (56), under "Other Publications", in column 2, line 7, delete "Etodalac" and insert - - Etodolac - -, therefor.

On page 3, in field (56), under "Other Publications", in column 2, line 33, delete "Ademomas" and insert - - Adenomas - -, therefor.

MAILING ADDRESS OF SENDER:

PATENT NO. _____7,151,100___

SCHWEGMAN, LUNDBERG, WOESSNER, & KLUTH, P.A. P.O. BOX 2938 Minneapolis, MN 55402

No. of additional copies

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO

: 7.151.100

Page (2) of 3

DATED

: December 19, 2006

INVENTOR(S)

: Carson et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On page 3, in field (56), under "Other Publications", in column 2, line 37, delete "Flubiprofen" and insert - - Flurbiprofen - -, therefor.

On page 3, in field (56), under "Other Publications", in column 2, line 38, delete "Enatiomer" and insert - - Enantiomer - -, therefor.

On Sheet 4 of 15, in FIG. 4, line 7 (Excluding Graph), delete "50 μ M" and insert - - 50 μ M - -, therefor.

In column 1, line 7, after "1999," insert - - now U.S. Patent No. 6,545,034, - -.

In column 2, lines 60–61, delete "1'-D-glucuronyloxy," and insert - - $OCH_2CH_2N(CH_3)^{\dagger}_3$, or 1'-D-glucuronyloxy; or Y-Z is $(CH_2)_{1-3}R^{10}$ wherein R^{10} is - -, therefor.

In column 2, line 62, after "PO(OH)NH₂," delete "OCH₂CH₂N(CH₃)¹,".

In column 2, line 65, delete "calls" and insert - - cells - -, therefor.

In column 3, line 9, delete "chromic" and insert - - chronic - -, therefor.

In column 3, line 33, delete "chlorodenosine" and insert - - chloroadenosine - -, therefor.

In column 3, line 34, delete "chemoterapeutic" and insert - - chemotherapeutic - -, therefor.

In column 3, line 64, after "cancer" insert - - cell - -.

In column 5, line 45, delete "or" and insert - - OCH₂CH₂N(CH₃)⁺₃, - -, therefor.

In column 5, line 46, after "alkylamino," insert - - [(carboxy)(lower alkyl)] - -.

In column 5, line 47, after "phenylamino," insert - - or Y-Z is $(CH_2)_{1-3}R^{10}$ wherein

R¹⁰ is - -.

JUN 2 0 2007


In column 5, line 48, after "OCH₂CH₂N(CH₃) $^{\dagger}_{3}$ " insert - - , - -.

MAILING ADDRESS OF SENDER:


P.O. BOX 2938 Minneapolis, MN 55402 PATENT NO. _____7,151,100____

No. of additional copies

 \Rightarrow



SCHWEGMAN, LUNDBERG, WOESSNER, & KLUTH, P.A.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO

: 7,151,100

Page (3) of 3

DATED

: December 19, 2006

INVENTOR(S)

: Carson et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 6, line 27, delete "metabolutes" and insert - - metabolites - -, therefor.

In column 7, line 48, delete "to" and insert - - of - -, therefor.

In column 8, line 47, delete "othewise" and insert - - otherwise - -, therefor.

In column 9, line 38, after "the" insert - - preferred methods of preparation are vacuum drying and the freeze drying - -.

In column 10, line 3, delete "Lympocytes" and insert - - Lymphocytes - -, therefor.

In column 10, line 59, delete "Chromagtog" and insert - - Chromatog - -, therefor.

In column 14, line 4, delete "residuel" and insert - residual - -, therefor.

In column 14, line 40, delete "radiolbeled" and insert - - radiolabeled - -, therefor.

In column 14, line 47, delete "syste" and insert - - system - -, therefor.

In column 14, line 60, delete "mg" and insert - - ng - -, therefor.

In column 16, lines 27–34, in Claim 1, delete "wherein R⁸ and R⁹ are each H, (C₁-C₃)alkyl or. together with N, are a 5- or 6-membered heterocyclic ring having 1-3 N(R8), S or nonperoxide O, an amino acid ester of $(\omega$ -(HO)(C₂-C₄)) alkoxy, N (R⁸) CH (R⁸) CO₂H, 1'-D-glucuronyloxy, OH, (C_2-C_4) acyloxy, SO_3H , PO_4H_2 , N(NO)(OH), SO_2NH_2 , $PO(OH)(NH_2)$, $OCH_2CH_2N(CH_3)^{\dagger}_3$, amino, lower alkylamino, di(lower alkyl)amino, phenylamino," and insert - - an amino acid ester of $(\omega$ -(HO)(C₂-C₄))alkoxy, N(R⁸)CH(R⁸)CO₂H, 1'-D-glucuronyloxy, or OCH₂CH₂N(CH₃) $^{+}_{3}$; wherein R⁸ and R⁹ are each H, (C₁-C₃)alkyl or together with N, are a 5- or 6-membered heterocyclic ring having 1-3 N(R⁸), S or nonperoxide O; or Y-Z is (CH₂)₁₋₃R¹⁰ wherein R¹⁰ is OH, (C₂-C₄)acyloxy, SO₃H, PO₄H₂, N(NO)(OH), SO₂NH₂, PO(OH)NH₂, --, therefor.

MAILING ADDRESS OF SENDER:

PATENT NO. _____7,151,100____

SCHWEGMAN, LUNDBERG, WOESSNER, & KLUTH, P.A. P.O. BOX 2938 Minneapolis, MN 55402

No. of additional copies

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO

: 7,151,100

Page (1) of 3

DATED

: December 19, 2006

INVENTOR(S)

: Carson et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the face page, in field (63), under "Related U.S. Application Data", in column 1, line 2, after "1999" insert - - , now Pat. No. 6,545,034 - -.

On the face page, in field (56), under "Foreign Patent Documents", in column 1, line 13, delete "WO-02/021225" and insert - - WO-02/02125 - -, therefor.

On page 2, in field (56), under "U.S. Patent Documents", in column 1, line 32, below "5,824,699" insert - - 5,939,455 8/1999 Rephaeli 514/547 - -.

On page 2, in field (56), under "U.S. Patent Documents", in column 1, line 43, below "2002/0042375" insert - - 2003/0004142 1/2003 Prior et al. 514/165 - -.

On page 2, in field (56), under "Other Publications", in column 2, lines 38-41, delete ""Treatment of Prostate Cancer: Watchful Waiting, Radical Prostatectomy, and Cryoablation", Seminars in Surgical Oncology, 18(1), pp. 37-44, Jan./Feb. 2000)" and insert - - "Enhancement of Chemotherapeutic Drug Toxicity to Human Tumour Cells In Vitro by a Subset of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)", European Journal of Cancer, 34 (8), pp. 1250-1259, (Jul. 1998). - -, therefor.

On page 2, in field (56), under "Other Publications", in column 2, line 61, below "1997)." insert - - Leman, Eddy S., et al., "Characterization of the Nuclear Matrix Proteins in a Transgenic Mouse Model for Prostate Cancer", Journal of Cellular Biochemistry, 86, (2002), 203-212.".

On page 3, in field (56), under "Other Publications", in column 2, line 7, delete "Etodalac" and insert - - Etodolac - -, therefor.

On page 3, in field (56), under "Other Publications", in column 2, line 33, delete "Ademomas" and insert - - Adenomas - -, therefor.

MAILING ADDRESS OF SENDER:

PATENT NO. ______7,151,100

SCHWEGMAN, LUNDBERG, WOESSNER, & KLUTH, P.A. P.O. BOX 2938 Minneapolis, MN 55402

No. of additional copies

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE **CERTIFICATE OF CORRECTION**

PATENT NO

: 7,151,100

Page (2) of 3

DATED

: December 19, 2006

INVENTOR(S)

: Carson et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On page 3, in field (56), under "Other Publications", in column 2, line 37, delete "Flubiprofen" and insert - - Flurbiprofen - -, therefor.

On page 3, in field (56), under "Other Publications", in column 2, line 38, delete "Enatiomer" and insert - - Enantiomer - -, therefor.

On Sheet 4 of 15, in FIG. 4, line 7 (Excluding Graph), delete "50uM" and insert - - 50 μ M - -, therefor.

In column 1, line 7, after "1999," insert - - now U.S. Patent No. 6,545,034, - -.

In column 2, lines 60–61, delete "1'-D-glucuronyloxy," and insert - - $OCH_2CH_2N(CH_3)^{\dagger}_3$, or 1'-D-glucuronyloxy; or Y-Z is $(CH_2)_{1-3}R^{10}$ wherein R^{10} is - -, therefor.

In column 2, line 62, after "PO(OH)NH₂," delete "OCH₂CH₂N(CH₃)¹,".

In column 2, line 65, delete "calls" and insert - - cells - -, therefor.

In column 3, line 9, delete "chromic" and insert - - chronic - -, therefor.

In column 3, line 33, delete "chlorodenosine" and insert - - chloroadenosine - -, therefor,

In column 3, line 34, delete "chemoterapeutic" and insert - - chemotherapeutic - -, therefor.

In column 3, line 64, after "cancer" insert - - cell - -.

In column 5, line 45, delete "or" and insert - - OCH₂CH₂N(CH₃)⁺₃, - -, therefor.

In column 5, line 46, after "alkylamino," insert - - [(carboxy)(lower alkyl)] - -.

In column 5, line 47, after "phenylamino," insert - - or Y-Z is (CH₂)₁₋₃R¹⁰ wherein R¹⁰ is - -.

In column 5, line 48, after "OCH₂CH₂N(CH₃) † " insert - - , - -.

MAILING ADDRESS OF SENDER:

PATENT NO. _____7,151,100___

SCHWEGMAN, LUNDBERG, WOESSNER, & KLUTH, P.A. P.O. BOX 2938 Minneapolis, MN 55402

Atty Docket No: 103.022US1

No. of additional copies

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO

: 7,151,100

Page (3) of 3

DATED

: December 19, 2006

INVENTOR(S)

: Carson et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 6, line 27, delete "metabolutes" and insert - - metabolites - -, therefor.

In column 7, line 48, delete "to" and insert - - of - -, therefor.

In column 8, line 47, delete "othewise" and insert - - otherwise - -, therefor.

In column 9, line 38, after "the" insert - - preferred methods of preparation are vacuum drying and the freeze drying - -.

In column 10, line 3, delete "Lympocytes" and insert - - Lymphocytes - -, therefor.

In column 10, line 59, delete "Chromagtog" and insert - - Chromatog - -, therefor.

In column 14, line 4, delete "residuel" and insert - - residual - -, therefor.

In column 14, line 40, delete "radiolbeled" and insert - - radiolabeled - -, therefor,

In column 14, line 47, delete "syste" and insert - - system - -, therefor.

In column 14, line 60, delete "mg" and insert - - ng - -, therefor.

In column 16, lines 27–34, in Claim 1, delete "wherein R⁸ and R⁹ are each H, (C₁-C₃)alkyl or, together with N, are a 5- or 6-membered heterocyclic ring having 1-3 N(R8), S or nonperoxide O, an amino acid ester of $(\omega$ -(HO)(C₂-C₄)) alkoxy, N (R⁸) CH (R⁸) CO₂H, 1'-D-glucuronyloxy, OH, (C_2-C_4) acyloxy, SO_3H , PO_4H_2 , N(NO)(OH), SO_2NH_2 , $PO(OH)(NH_2)$, $OCH_2CH_2N(CH_3)^{+}_3$, amino, lower alkylamino, di(lower alkyl)amino, phenylamino," and insert - - an amino acid ester of $(\omega$ -(HO)(C₂-C₄))alkoxy, N(R⁸)CH(R⁸)CO₂H, 1'-D-glucuronyloxy, or OCH₂CH₂N(CH₃) $^{+}_{3}$; wherein R⁸ and R⁹ are each H, (C₁-C₃)alkyl or together with N, are a 5- or 6-membered heterocyclic ring having 1-3 N(R⁸), S or nonperoxide O; or Y-Z is (CH₂)₁₋₃R¹⁰ wherein R¹⁰ is OH, (C₂-C₄)acyloxy, SO₃H, PO₄H₂, N(NO)(OH), SO₂NH₂, PO(OH)NH₂, --, therefor.

PATENT NO. _____7,151,100__

SCHWEGMAN, LUNDBERG, WOESSNER, & KLUTH, P.A. P.O. BOX 2938 Minneapolis, MN 55402

No. of additional copies



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dennis A. Carson et al.

Examiner: Ward, Paul

Patent No.: 7,151,100

Group Art Unit: 1624

Issue Date: December 19, 2006

Docket No: 103.022US1

Title: INDOLE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

ATTN: CERTIFICATE OF CORRECTION BRANCH

We are transmitting herewith the attached:

- X A check in the amount of \$100.00 to cover the Certificate of Correction fee.
- X Request for Certificate of Correction.
- X Certificate of Correction Form PTO-1050 (in duplicate)
- X A return postcard.

Please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

Customer No: 21186

By: Monique M. Perdok Shonka

ushen Bartell

Reg. No.42,989 MMP:CMG:sj

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents and Trademarks, P.O. Box 1450, Alexandria VA 22313-1450, on this 4 day of 5 June 2007.

Leshere Bortll

Signature